Brostallicin (PNU-166196) - A new DNa minor groove binder that retains sensitivity in DNa mismatch repair-deficient tumour cells

British Journal of Cancer

Volumn 89, Issue 8, 2003, Pages 1559-1565

  Fedier, A ^a   Fowst, C ^b   Tursi, J ^b   Geroni, C ^b   Haller, U ^a   Marchini, S ^c   Fink, D ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b PFIZER INC   (United States)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Brostallicin; DNA minor groove binder; DNA mismatch repair; Drug sensitivity

Indexed keywords

ANTINEOPLASTIC AGENT; BROSTALLICIN; DISTAMYCIN A; DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PNU 152241; PROTEIN P53; TALLIMUSTINE; TAQ POLYMERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DNA ALKYLATION; DRUG DNA BINDING; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; ENDOMETRIUM CARCINOMA; FIBROBLAST; HUMAN; HUMAN CELL; MISMATCH REPAIR; MOUSE; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

EID: 0242490457     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601316     Document Type: Article

References (41)

1. Bailey SM, Meyne J, Chen DJ, Kurimasa A, Li GC, Lehnert BE, Goodwin EH (1999) DNA double-strand break repair proteins are required to cap the ends of mammalian chromosomes. Proc Natl Acad Sci USA 96: 14899-14904
2. Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, Barrett JC, Kolodner RD, Kunkel TA (1995) Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 55: 6063-6070
3. Branch P, Hampson R, Karran P (1995) DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 55: 2304-2309
4. Broggini M, Coley HM, Mongelli N, Pesenti E, Wyatt MD, Hartley JA, D'Incalci M (1995) DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res 23: 81-87
5. Broggini M, Erba E, Ponti M, Ballinari D, Geroni C, Spreafico F, D'Incalci M (1991) Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res 51: 199-204
6. Colella G, Marchini S, D'Incalci M, Brown R, Broggini M (1999) Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br J Cancer 80: 338-343
7. Cozzi P (2000) Recent outcome in the field of distamycin-derived minor groove binders. Farmaco 55: 168-173
8. Cozzi P (2003) The discovery of a new potential anticancer drug: a case history. Farmaco 58: 213-220
9. D'Alessio R, Geroni C, Biasoli G, Pesenti E, Grandi M, Mongelli N (1994) Structure - activity relationship of novel distamycin A derivatives: synthesis and antitumor activity. Bioorganic Med Chem Lett 4: 1467-1472
10. D'Incalci M (1994) DNA-minor groove alkylators, a new class of anticancer agents. Ann Oncol 5: 877-878
11. Drummond JT, Anthoney DA, Brown R, Modrich P (1996) Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271: 19645-19648
12. Fedier A, Ruefenacht UB, Schwarz VA, Haller U, Fink D (2002) Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2. Br J Cancer 87: 1027-1033
13. Fedier A, Schwarz VA, Walt H, Delli Carpini R, Haller U, Fink D (2001) Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 93: 571-576
14. Ferreira CG, Tolis C, Giaccone G (1999) p53 and chemosensitivity. Ann Oncol 10: 1011-1021
15. Fink D, Aebi S, Howell SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4: 1-6
16. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886
17. Geroni C, Marchini S, Cozzi P, Galliera E, Ragg E, Colombo T, Battaglia R, Howard M, D'Incalci M, Broggini M (2002) Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to gluthathione. Cancer Res 62: 2332-2336
18. Hartley JA, Lown JW, Mattes WB, Kohn KW (1988) DNA sequence specificity of antitumor agents. Oncogenes as possible targets for cancer therapy. Acta Oncol 27: 503-510
19. Hertzberg RP, Dervan PB (1984) Cleavage of DNA with methidiumpropyl-EDTA- iron(II): reaction conditions and product analyses. Biochemistry 14: 3934-3945
20. Hollstein M, Sidransky B, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253: 49-53
21. Hurley LH, Reynolds VL, Swenson DH, Petzold GL, Scahill TA (1984) Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with sequence specificity. Science 226: 843-844
22. Jackson SP (1997) DNA-dependent protein kinase. Int J Biochem Cell Biol 29: 935-938
23. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N- nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308-4312
24. Lee M, Rhodens VL, Wyatt MD, Forrow S, Hartley JA (1993) Design, synthesis, and biological evaluation of DNA sequence and minor groove selective alkylating agents. Anticancer Drug Des 8: 173-193
25. Li LH, Dekonong TF, Kelly RC, Krueger WC, McGovren JP, Padbury GE, Petzold GL, Wallace TL, Ouding RJ, Prairie MD, Gebhard I (1992) Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res 52: 4904-4913
26. Li LH, Swenson D, Schpock S, Kuentzel S, Dayton B, Kreiger W (1982) CC-1065 (NSC-298223) a novel antitumor agent that interacts strongly with double-strand DNA. Cancer Res 42: 999-1104
27. Marchini S, Ciro M, Gallinari F, Cozzi P, D'Incalci M, Broggini M (1999) Bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity. Br J Cancer 80: 991-997
28. Marchini S, Cozzi P, Beria I, Geroni C, Capolongo L, D'Incalci M, Broggini M (1998) Sequence specific alkylation of novel tallimustine derivatives. Anticancer Drug Design 13: 193-205
29. Martin DG, Biles C, Gerpheide SA, Hanka LJ, Krueger WC, McGovren JP, Mizsak SA, Neil GL, Stewart JC, Visser J (1981) CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity. J Antibiot Tokyo 34: 1119-1125
30. Modrich P (1991) Mechanisms and biological effects of DNA mismatch repair. Ann Rev Genet 25: 229-253
31. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63
32. Peltomaki P (2001) DNA mismatch repair and cancer. Mutat Res 488: 77-85
33. Ponti M, Forrow SM, Souhami RL, D'Incalci M, Hartley JA (1991) Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase. Nucleic Acids Res 19: 2929-2933
34. Reynolds VL, Molineux IJ, Kaplan DJ, Swenson DH, Hurley LH (1985) Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity. Biochemistry 24: 6228-6237
35. Schwarz VA, Hornung R, Fedier A, Walt H, Haller U, Fink D (2002) Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells. Br J Cancer 86: 1130-1135
36. Smith GC, Cary RB, Lakin ND, Hann BC, Teo SH, Chen DJ, Jackson SP (1999) Purification and DNA binding properties of the ataxiatelangiectasia gene product ATM. Proc Natl Acad Sci USA 96: 11134-11139
37. Sun D, Hurley LH (1992) Effect of the (+)-CC1065-(N3-adenine) DNA adduct on in vitro DNA synthesis mediated by Escherichia coli DNA polymerase. Biochemistry 31: 2822-2829
38. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, Boland CR, Barrett JC, Kunkel TA (1997) Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 57: 3949-3955
39. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14: 927-939
40. Westphal CH, Schmaltz C, Rowan S, Elson A, Fisher DE, Leder P (1997) Genetic interactions between ATM and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. Cancer Res 57: 1664-1667
41. Zeng M, Narayanan L, Xu XS, Prolla TA, Liskay MR, Glazer PM (2000) Ionizing radiation-induced apoptosis via separate pms2-and p53-dependent pathways. Cancer Res 60: 4889-4893